Advertisement


Samuel M. Silver, MD, PhD, and Margaret A. Tempero, MD, on Multidisciplinary Management of Pancreatic Cancer

2015 NCCN Annual Conference

Advertisement

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed for hematologic malignancies that have activity in pancreatic cancer, vaccines, neoadjuvant treatment, and the need to focus on activated RAS.



Related Videos

Leukemia

William G. Wierda, MD, PhD, on Updates to the Management of CLL

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses the latest information on managing CLL and his optimism that a cure is in sight.

Lung Cancer

John C. Grecula, MD, on the Role of Radiation Therapy in Management of SCLC

John C. Grecula, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of precision delivery of radiation for patients with small cell lung cancer and advances that include prophylactic cranial radiotherapy, thoracic radiotherapy, and the use of PET-CT.

Breast Cancer

Ingrid A. Mayer, MD, on New Therapies for Hormone-Sensitive Advanced Breast Cancer

Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discusses the evolution of endocrine therapy for metastatic breast cancer.

Peter G. Shields, MD, on New NCCN Guidelines: Smoking Cessation for Patients With Cancer

Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the new NCCN Guidelines for helping patients with cancer to stop smoking. Counseling is a critical part of these new recommendations.

Lung Cancer

Leora Horn, MD, MSc, on Targeted and Emerging Therapies for Metastatic NSCLC

Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.

Advertisement

Advertisement




Advertisement